|
Market Cap | 25.46M | EPS (ttm) | -13.43 |
P/E | - | EPS this Y | 20.59% |
Forward P/E | - | EPS next Y | 20.86% |
PEG | - | EPS past 5Y | 18.19% |
P/S | 32.22 | EPS next 5Y | 0.00% |
P/B | 0.84 | EPS Q/Q | 22.86% |
Dividend | - | Sales Q/Q | 73.68% |
Insider Own | 9.78% | Inst Own | 14.13% |
Insider Trans | 3.58% | Inst Trans | -72.82% |
Short Float | 0.63% | Earnings | Mar 07/a |
Analyst Recom | 1.50 | Target Price | 31.33 |
Avg Volume | 10.46K | 52W Range | 5.57 - 13.14 |
|
|
|
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Wills Robert James | Director | Apr 08 '24 | Buy | 8.96 | 3,086 | 27,655 | 10,000 | Apr 10 08:38 PM | Wills Robert James | Director | Mar 28 '24 | Buy | 8.48 | 6,914 | 58,602 | 6,914 | Apr 01 07:00 PM | HALE DAVID F | Director | Feb 23 '24 | Buy | 9.04 | 714 | 6,455 | 714 | Feb 27 05:03 PM | HALE DAVID F | Director | Feb 23 '24 | Buy | 9.04 | 266 | 2,405 | 29,673 | Feb 27 05:03 PM | Wills Robert James | Director | Feb 23 '24 | Sale | 9.04 | 980 | 8,859 | 0 | Feb 27 05:02 PM |
|
|
|
|
Market Cap | 466.60M | EPS (ttm) | -1.78 |
P/E | - | EPS this Y | 13.88% |
Forward P/E | - | EPS next Y | -7.79% |
PEG | - | EPS past 5Y | -29.69% |
P/S | - | EPS next 5Y | 38.60% |
P/B | 1.39 | EPS Q/Q | 24.94% |
Dividend | - | Sales Q/Q | - |
Insider Own | 21.24% | Inst Own | 66.36% |
Insider Trans | 1.42% | Inst Trans | 11.82% |
Short Float | 4.34% | Earnings | Mar 26/a |
Analyst Recom | 1.00 | Target Price | 15.17 |
Avg Volume | 1.56M | 52W Range | 1.57 - 8.40 |
|
|
|
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Carson William H. | Director | Apr 08 '24 | Buy | 6.07 | 3,200 | 19,411 | 3,200 | Apr 10 07:17 PM | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Feb 20 '24 | Sale | 5.51 | 2,604 | 14,348 | 72,471 | Feb 21 04:31 PM | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Feb 20 '24 | Sale | 5.53 | 2,593 | 14,339 | 82,058 | Feb 21 04:31 PM | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Feb 20 '24 | Sale | 5.48 | 1,951 | 10,691 | 85,641 | Feb 21 04:31 PM | Love Douglas | PRESIDENT AND CEO | Feb 12 '24 | Sale | 5.54 | 5,782 | 32,032 | 196,121 | Feb 14 07:56 PM |
|
|
|
|
Market Cap | 9.75M | EPS (ttm) | -3.54 |
P/E | - | EPS this Y | 37.72% |
Forward P/E | - | EPS next Y | 1.17% |
PEG | - | EPS past 5Y | 77.95% |
P/S | 64.99 | EPS next 5Y | - |
P/B | 0.59 | EPS Q/Q | 49.37% |
Dividend | - | Sales Q/Q | 421.62% |
Insider Own | 27.60% | Inst Own | 11.39% |
Insider Trans | 18.21% | Inst Trans | 2.02% |
Short Float | 0.83% | Earnings | - |
Analyst Recom | 1.00 | Target Price | 10.50 |
Avg Volume | 657.55K | 52W Range | 1.20 - 7.13 |
|
|
|
BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Silva Francisco | VP of Research and Development | Apr 09 '24 | Buy | 1.25 | 6,600 | 8,250 | 155,759 | Apr 10 05:16 PM | Silva Francisco | VP of Research and Development | Apr 08 '24 | Buy | 1.16 | 1,708 | 1,979 | 149,159 | Apr 10 05:16 PM | Broadrick Dale | 10% Owner | Feb 09 '24 | Buy | 1.32 | 86,041 | 113,574 | 477,972 | Feb 12 09:26 AM | Broadrick Dale | 10% Owner | Feb 08 '24 | Buy | 1.34 | 83,626 | 112,059 | 447,045 | Feb 09 08:00 AM | Broadrick Dale | 10% Owner | Feb 08 '24 | Buy | 1.25 | 73,959 | 92,449 | 391,931 | Feb 12 09:26 AM |
|
|
| |
|
Market Cap | 400.18M | EPS (ttm) | -0.25 |
P/E | - | EPS this Y | -1152.00% |
Forward P/E | - | EPS next Y | -38.78% |
PEG | - | EPS past 5Y | -5.52% |
P/S | 3.10 | EPS next 5Y | - |
P/B | 1.64 | EPS Q/Q | 63.59% |
Dividend | - | Sales Q/Q | - |
Insider Own | 46.49% | Inst Own | 47.87% |
Insider Trans | -0.05% | Inst Trans | -0.82% |
Short Float | 9.82% | Earnings | Mar 13/b |
Analyst Recom | 1.00 | Target Price | 21.00 |
Avg Volume | 76.36K | 52W Range | 10.62 - 18.44 |
|
|
|
Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
KIM PETER S | Director | Apr 08 '24 | Buy | 13.57 | 2,600 | 35,290 | 62,936 | Apr 10 04:35 PM | KIM PETER S | Director | Mar 28 '24 | Buy | 13.75 | 1,512 | 20,794 | 60,336 | Apr 01 04:31 PM | KIM PETER S | Director | Mar 26 '24 | Buy | 13.64 | 2,750 | 37,509 | 58,824 | Mar 26 05:57 PM | KIM PETER S | Director | Mar 25 '24 | Buy | 13.36 | 3,180 | 42,472 | 56,074 | Mar 26 05:57 PM | KIM PETER S | Director | Mar 22 '24 | Buy | 13.76 | 3,118 | 42,901 | 52,894 | Mar 26 05:57 PM |
|
|
|
|
Market Cap | 16.60M | EPS (ttm) | -4.33 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 8.14 | EPS next 5Y | - |
P/B | 0.31 | EPS Q/Q | 19.43% |
Dividend | - | Sales Q/Q | - |
Insider Own | 14.65% | Inst Own | 7.88% |
Insider Trans | 20.49% | Inst Trans | 16.15% |
Short Float | 0.04% | Earnings | - |
Analyst Recom | 1.00 | Target Price | 16.00 |
Avg Volume | 12.05K | 52W Range | 1.76 - 3.76 |
|
|
|
Dominari Holdings, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Wool Kyle Michael | President | Apr 08 '24 | Buy | 2.99 | 8,500 | 25,390 | 22,750 | Apr 10 04:10 PM | Hayes Anthony | CEO | Apr 05 '24 | Buy | 2.88 | 13,500 | 38,823 | 116,248 | Apr 08 04:10 PM | Wool Kyle Michael | President | Apr 04 '24 | Buy | 2.87 | 19,000 | 54,511 | 18,500 | Apr 08 04:10 PM | Hayes Anthony | CEO | Apr 04 '24 | Buy | 2.62 | 3,944 | 10,339 | 102,748 | Apr 08 04:10 PM | Devall Christopher Franklin | COO | Dec 26 '23 | Buy | 2.55 | 7,000 | 17,863 | 30,033 | Dec 28 08:00 AM |
|
|
| |
|
Market Cap | 103.74M | EPS (ttm) | 0.09 |
P/E | 28.45 | EPS this Y | 190.91% |
Forward P/E | 10.23 | EPS next Y | 160.00% |
PEG | 7.90 | EPS past 5Y | - |
P/S | 0.14 | EPS next 5Y | 3.60% |
P/B | - | EPS Q/Q | 162.45% |
Dividend | 0.75% | Sales Q/Q | -26.05% |
Insider Own | 27.84% | Inst Own | 35.33% |
Insider Trans | 2.64% | Inst Trans | 1.12% |
Short Float | 0.22% | Earnings | Apr 17/a |
Analyst Recom | 3.00 | Target Price | 3.50 |
Avg Volume | 44.96K | 52W Range | 1.95 - 3.30 |
|
|
|
Martin Midstream Partners LP engages in a diverse set of operations focused primarily in the United States Gulf Coast region. It operates through the following segments: Terminalling and Storage, Transportation, Sulfur Services, and Natural Gas Liquids. The Terminalling and Storage segment offers storage, refining, blending, packaging, and handling services for producers and suppliers of petroleum products and by-products, including the refining of naphthenic crude oil and the blending and packaging of various grades and quantities of industrial, commercial, and automotive lubricants and greases. The Transportation segment manages a fleet of inland marine tank barges, inland push boats and offshore tug, and barge unit that transport petroleum products and by-products. The Sulfur Services segment develops an integrated system of transportation assets and facilities relating to sulfur services. The Natural Gas Liquids segment distributes natural gas liquids. The company was founded in 2002 and is headquartered in Kilgore, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
BONDURANT ROBERT D | President and CEO | Apr 09 '24 | Buy | 2.65 | 1,603 | 4,243 | 148,070 | Apr 10 12:57 PM | MARTIN RUBEN S | Director | Apr 09 '24 | Buy | 2.65 | 821 | 2,173 | 158,800 | Apr 10 12:57 PM | Taylor Sharon L | Executive Vice President / CFO | Apr 09 '24 | Buy | 2.65 | 398 | 1,053 | 23,034 | Apr 10 12:57 PM | Shoup Scot A | Senior VP Operations | Apr 09 '24 | Buy | 2.65 | 176 | 466 | 27,846 | Apr 10 12:57 PM | BONDURANT ROBERT D | President and CEO | Mar 12 '24 | Buy | 2.56 | 1,106 | 2,829 | 146,467 | Mar 14 11:07 AM |
|
|
|
|
Market Cap | 88.91M | EPS (ttm) | 0.05 |
P/E | 142.46 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -31.37% |
P/S | 2.31 | EPS next 5Y | - |
P/B | 0.65 | EPS Q/Q | -164.57% |
Dividend | - | Sales Q/Q | 6.62% |
Insider Own | 66.91% | Inst Own | 7.91% |
Insider Trans | 0.38% | Inst Trans | -3.69% |
Short Float | 0.21% | Earnings | Feb 06/a |
Analyst Recom | 3.00 | Target Price | 12.00 |
Avg Volume | 6.08K | 52W Range | 6.46 - 9.43 |
|
|
|
Bogota Financial Corp. is a holding company, which engages in the provision of business activities that are permissible for mutual holding companies under New Jersey law, including investing in loans and securities. It includes the acquisition of banking and financial services companies. It operates through the following loan portfolio: residential first mortgage, commercial and multi-family real estate, construction, home equity and other, and commercial and industrial. The company was founded in September 2019 and is headquartered in Teaneck, NJ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Walsh Robert C. | Executive Vice President | Apr 09 '24 | Buy | 6.84 | 250 | 1,710 | 4,750 | Apr 10 12:09 PM | Masterson John J. | Director | Mar 15 '24 | Buy | 7.30 | 1,400 | 10,220 | 172,584 | Mar 15 05:06 PM | Pace Kevin | President and CEO | Mar 15 '24 | Buy | 7.30 | 125 | 912 | 43,903 | Mar 18 10:23 AM | Masterson John J. | Director | Mar 14 '24 | Buy | 7.30 | 1,929 | 14,082 | 171,184 | Mar 15 05:06 PM | Pace Kevin | President and CEO | Mar 08 '24 | Buy | 7.37 | 75 | 552 | 43,778 | Mar 08 05:14 PM |
|
|
| |
|
Market Cap | 728.14M | EPS (ttm) | 1.12 |
P/E | 12.55 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | - |
Dividend | 11.79% | Sales Q/Q | - |
Insider Own | - | Inst Own | 30.68% |
Insider Trans | - | Inst Trans | - |
Short Float | 0.05% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 200.67K | 52W Range | 12.16 - 14.69 |
|
|
|
Western Asset Diversified Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is to seek high current income. As a secondary investment objective, the Fund seek capital appreciation. Under normal circumstances, the Fund invest across fixed income sectors and securities to deliver a well-diversified portfolio. The Fund may invest in investment-grade and high-yield corporate debt securities, senior loans, agency and non-agency residential mortgage-backed securities (RMBS) and commercial mortgage-backed securities (CMBS), bank loans, collateralized loan obligations (CLOs), asset-backed securities, private debt and mortgage whole loans. The Fund may invest up to 15% of its managed assets in securities issued by CLOs, including up to 5% of its managed assets in equity securities issued by CLOs, including subordinated, or residual tranches of CLO securities). The Fund's investment manager is Legg Mason Partners Fund Advisor, LLC. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Kumar Nisha | Director | Apr 08 '24 | Buy | 14.46 | 6,225 | 90,006 | 13,725 | Apr 10 11:51 AM | Kumar Nisha | Director | Jan 23 '24 | Buy | 14.09 | 7,500 | 105,675 | 7,500 | Jan 24 06:01 PM | Kumar Nisha | Director | Jan 22 '24 | Buy | 14.16 | 9,000 | 127,440 | 9,000 | Jan 24 06:01 PM | CRONIN DANIEL P | Director | Oct 23 '23 | Buy | 12.42 | 5,000 | 62,100 | 5,000 | Oct 24 05:03 PM |
|
|
|
|
Market Cap | 242.54M | EPS (ttm) | -3.26 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 3.93 | EPS next 5Y | - |
P/B | 0.27 | EPS Q/Q | - |
Dividend | 9.54% | Sales Q/Q | - |
Insider Own | 18.92% | Inst Own | 51.08% |
Insider Trans | 0.55% | Inst Trans | 1.20% |
Short Float | 0.63% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 123.13K | 52W Range | 5.82 - 13.07 |
|
|
|
NexPoint Diversified Real Estate Trust is a real estate investment trust, which engages in the business of acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties. The firm is also involved in investing in various commercial real estate property types and across the capital structure including equity, mortgage debt, mezzanine debt, and preferred equity. The company was founded on March 10, 2006 and is headquartered in Dallas, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
LAFFER ARTHUR B | Director | Apr 09 '24 | Buy | 6.17 | 20,000 | 123,400 | 88,276 | Apr 10 11:13 AM | LAFFER ARTHUR B | Director | Apr 08 '24 | Buy | 6.12 | 20,000 | 122,400 | 68,276 | Apr 10 11:13 AM | DONDERO JAMES D | See Remarks | Oct 06 '23 | Buy | 14.20 | 373 | 5,297 | 20,797 | Oct 10 04:15 PM | DONDERO JAMES D | See Remarks | Oct 05 '23 | Buy | 14.20 | 2,081 | 29,550 | 20,424 | Oct 10 04:15 PM | KAVANAUGH SCOTT F | Director | Aug 17 '23 | Sale | 10.62 | 1,131 | 12,006 | 0 | Aug 17 04:30 PM |
|
|
|
|
Market Cap | 59.33M | EPS (ttm) | 0.40 |
P/E | 42.86 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -30.30% |
P/S | 1.89 | EPS next 5Y | - |
P/B | 0.78 | EPS Q/Q | -189.50% |
Dividend | 6.35% | Sales Q/Q | -58.43% |
Insider Own | 57.80% | Inst Own | 8.65% |
Insider Trans | 0.04% | Inst Trans | 4.75% |
Short Float | 0.26% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 3.05K | 52W Range | 16.80 - 23.75 |
|
|
|
Auburn National Bancorporation, Inc. is a bank holding company. It engages in the provision of banking services to commercial and retail customers. The firm operates through the following segments: Commercial and Industrial, Construction and Land Development, Commercial Real Estate, Residential Real Estate, and Consumer Installment. The Commercial and Industrial segment includes loans to finance business operations, equipment purchases, or other needs for small and medium-sized commercial customers. The Construction and Land Development segment is comprised of both loans and credit lines for the purpose of purchasing, carrying and developing land into commercial developments or residential subdivisions. The Commercial and Industrial segment provides loans disaggregated into three classes: owner occupied, multi-family and other. The Residential Real Estate segment is involved in consumer mortgage and investment property. The Consumer Installment segment encompasses loans to individuals both secured by personal property and unsecured. The company was founded in 1990 and is headquartered in Auburn, AL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Barrett J Tutt | Director | Apr 09 '24 | Buy | 19.25 | 93 | 1,791 | 8,553 | Apr 10 10:43 AM | HAM WILLIAM F JR | Director | Apr 09 '24 | Buy | 19.21 | 72 | 1,383 | 4,841 | Apr 10 10:59 AM | HOUSEL DAVID E | Director | Apr 09 '24 | Buy | 19.25 | 64 | 1,232 | 7,345 | Apr 10 10:27 AM | O'DONNELL SHANNON | Senior Vice President | Apr 09 '24 | Buy | 19.28 | 34 | 656 | 1,356 | Apr 10 10:06 AM | Barrett J Tutt | Director | Jan 02 '24 | Buy | 20.85 | 84 | 1,751 | 8,460 | Jan 03 12:23 PM |
|
|
|